Nanobiotix (NBTX) Expected to Announce Earnings on Monday

Key Points

• Nanobiotix (NBTX) is set to post earnings before the market opens on September 22, 2023, with analysts predicting a loss of ($0.2930) per share and revenue of $3.719 million for the quarter.
• The company's stock is experiencing a 6.0% decline and has a current trading price of $11.57, amidst historical lows of $2.76 and highs of $13.20 over the past year.
• Analysts have a consensus rating of "Moderate Buy" for Nanobiotix, with a price target set at $11.00 and a buy rating reaffirmed by HC Wainwright and a $14.00 target from Leerink Partners.

Nanobiotix (NASDAQ:NBTX - Get Free Report) is anticipated to issue its H1 2025 results before the market opens on Monday, September 22nd. Analysts expect the company to announce earnings of ($0.2930) per share and revenue of $3.7190 million for the quarter. Investors can find conference call details on the company's upcoming H1 2025 earningreport page for the latest details on the call scheduled for Thursday, September 25, 2025 at 11:40 AM ET.

Nanobiotix Trading Down 6.0%

Shares of NASDAQ NBTX traded down $0.74 during midday trading on Friday, hitting $11.57. 68,520 shares of the stock traded hands, compared to its average volume of 49,053. Nanobiotix has a one year low of $2.76 and a one year high of $13.20. The business has a 50 day moving average price of $7.97 and a two-hundred day moving average price of $5.31.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on NBTX shares. Leerink Partners set a $14.00 price objective on Nanobiotix in a report on Thursday. HC Wainwright restated a "buy" rating on shares of Nanobiotix in a report on Friday. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $11.00.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.